LH2-051
Product Specifications
UNSPSC Description
LH2-051 is a lysosome-enhancing lead compound, which promotes the lysosome biogenesis and the Aβ aggregate clearance through dopamine transporter-cyclin-dependent kinase 9-transcription factor EB (DAT-CDK9-TFEB) pathway. LH2-051 exhibits good pharmacokinetic characteristics in mouse models. LH2-051 is potential for ameliorating Aleheimer’s Disease[1].
Target Antigen
CDK; Dopamine Transporter
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage;Neuronal Signaling
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/lh2-051.html
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
COC1=C(OC)C=C(C(CCC2=CNC3=C2C=CC=C3)N(CC4CCOCC4)CC5)C5=C1
Molecular Weight
434.57
References & Citations
[1]Zhou J, et al., Discovery and Optimization of Tetrahydroisoquinoline Derivatives To Enhance Lysosome Biogenesis as Preclinical Candidates for the Treatment of Alzheimer's Disease. J Med Chem. 2024 Jun 13;67(11):8836-8861.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-161723/LH2-051-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-161723/LH2-051-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
2358754-22-8
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
